Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eftilagimod alpha for hospitalized COVID-19
2020-002009-25Phase 2Terminated
- Sponsor
- Fakultní nemocnice Plzeň
- Start
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of eftilagimod alpha in coronavirus disease 2019 (COVID-19), sponsored by Fakultní nemocnice Plzeň. Primary endpoint: Clinical status on 7-point ordinal scale at day 15. Started Jun 2020; status: terminated.
02
Drugs
eftilagimod alpha
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002009-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002009-25.